Application of PROTACs in Hematological Malignancies--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1921-1924, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-1010061
ABSTRACT
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules by utilizing the ubiquitin proteasome system (UPS) to degrade proteins of interest. PROTACs have exhibited unprecedented efficacy and specificity in degrading various oncogenic proteins because of their unique mechanism of action, ability to target "undruggable" and mutant proteins. A series of PROTACs have been developed to degrade multiple key protein targets for the treatment of hematologic malignancy. Notably, PROTACs that target BCL-XL, IRAK4, STAT3 and BTK have entered clinical trials. The known PROTACs that have the potential to be used to treat various hematological malignancies are systematically summarized in this review.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Hematológicas
/
Ubiquitina-Proteína Ligasas
/
Complejo de la Endopetidasa Proteasomal
/
Quimera Dirigida a la Proteólisis
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS